Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36820   clinical trials with a EudraCT protocol, of which   6079   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoarthritis of the Hip or Knee

    Summary
    EudraCT number
    2014-002598-13
    Trial protocol
    ES   BE   CZ   GB   NL   PL   FR   SK  
    Global end of trial date
    10 Oct 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Oct 2017
    First version publication date
    14 Oct 2017
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    42160443PAI3003
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02289716
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Janssen Research & Development LLC
    Sponsor organisation address
    Archimedesweg 29, Leiden, Netherlands, 2333CM
    Public contact
    Clinical Registry group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com
    Scientific contact
    Clinical Registry group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    10 Oct 2016
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    10 Oct 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to demonstrate the efficacy as measured by the changes from baseline to the end of Week 16 in the Western Ontario and McMaster University Osteoarthritis Index [WOMAC] pain and physical function subscale scores, safety, and tolerability of fulranumab subcutaneous (SC) injections as monotherapy compared with placebo SC injections in subjects who had signs and symptoms of osteoarthritis (OA) of the hip or knee that were not adequately controlled by their current pain therapy and who were planning a joint replacement surgery.
    Protection of trial subjects
    Safety was evaluated throughout the study and included monitoring of adverse event (AE), clinical laboratory testing, vital sign collection (including orthostatic testing), neurologic evaluation (abbreviated neurologic examination including an assessment of pupillary light reflex and signs consistent with carpal tunnel syndrome, Total Neuropathy Score-nurse [TNSn], Mini Mental State Examination [MMSE], autonomic nervous system dysfunction history, and carpal tunnel syndrome questionnaire), joint-related event evaluations (joint examinations and radiographs), numerical rating scale (NRS) for nonstudy joint pain, electrocardiograms (ECGs), physical examinations, and injection-site reactions. This study was conducted in accordance with the ethical principles that have their origin in the declaration of Helsinki and that are consistent with Good Clinical Practice (GCP) and applicable regulatory requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    14 Jul 2015
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety
    Long term follow-up duration
    12 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 1
    Country: Number of subjects enrolled
    Canada: 4
    Country: Number of subjects enrolled
    Czech Republic: 2
    Country: Number of subjects enrolled
    United Kingdom: 12
    Country: Number of subjects enrolled
    Poland: 4
    Country: Number of subjects enrolled
    United States: 18
    Worldwide total number of subjects
    41
    EEA total number of subjects
    19
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    24
    From 65 to 84 years
    17
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 41 subjects were randomized: 13 in the placebo group, 14 in the fulranumab (FUL) 1 mg every 4 weeks (Q4wk) group, and 14 in the fulranumab 3 mg (Q4wk) group (intent-to-treat [ITT] analysis set).

    Period 1
    Period 1 title
    Double-blind Treatment Phase
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Subject

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Subjects received 4 placebo subcutaneous (SC) injections (one injection every 4 weeks) for 16 weeks during double-blind treatment phase.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received 4 placebo SC injections (one injection every 4 weeks) for 16 weeks during double-blind treatment phase.

    Arm title
    Fulranumab 1 milligram (mg)
    Arm description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 1 mg for 16 weeks during double-blind treatment phase.
    Arm type
    Experimental

    Investigational medicinal product name
    Fulranumab 1 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received fulranumab 1 mg injection every 4 weeks for 16 weeks during double-blind treatment phase.

    Arm title
    Fulranumab 3 mg
    Arm description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 3 mg for 16 weeks during double-blind treatment phase.
    Arm type
    Experimental

    Investigational medicinal product name
    Fulranumab 3 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received fulranumab 3 mg injection every 4 weeks for 16 weeks during double-blind treatment phase.

    Number of subjects in period 1
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Started
    13
    14
    14
    Completed
    7
    6
    4
    Not completed
    6
    8
    10
         Study terminated by sponsor
    5
    7
    8
         Consent withdrawn by subject
    1
    -
    1
         Trial site terminated by sponsor
    -
    -
    1
         Lost to follow-up
    -
    1
    -
    Period 2
    Period 2 title
    24 Week Follow-up Phase
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Placebo
    Arm description
    Subjects who received placebo in treatment phase were followed for 24 weeks in this period.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Fulranumab 1 mg
    Arm description
    Subjects who received fulranumab 1 mg in treatment phase were followed for 24 weeks in this period.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Fulranumab 3 mg
    Arm description
    Subjects who received fulranumab 3 mg in treatment phase were followed for 24 weeks in this period.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 2
    Placebo Fulranumab 1 mg Fulranumab 3 mg
    Started
    8
    9
    10
    Completed
    6
    6
    6
    Not completed
    2
    3
    4
         Adverse event
    -
    -
    2
         Study terminated by sponsor
    2
    3
    2
    Period 3
    Period 3 title
    Limited Safety Follow-up (LSFU) Phase
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Placebo
    Arm description
    Subjects who received placebo in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Fulranumab 1 mg
    Arm description
    Subjects who received fulranumab 1 mg in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Fulranumab 3 mg
    Arm description
    Subjects who received fulranumab 3 mg in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.
    Arm type
    No intervention

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Number of subjects in period 3
    Placebo Fulranumab 1 mg Fulranumab 3 mg
    Started
    2
    3
    1
    Completed
    1
    2
    0
    Not completed
    1
    1
    1
         Study terminated by sponsor
    1
    -
    -
         Consent withdrawn by subject
    -
    1
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received 4 placebo subcutaneous (SC) injections (one injection every 4 weeks) for 16 weeks during double-blind treatment phase.

    Reporting group title
    Fulranumab 1 milligram (mg)
    Reporting group description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 1 mg for 16 weeks during double-blind treatment phase.

    Reporting group title
    Fulranumab 3 mg
    Reporting group description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 3 mg for 16 weeks during double-blind treatment phase.

    Reporting group values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg Total
    Number of subjects
    13 14 14 41
    Title for AgeCategorical
    Units: subjects
        Children (2-11 years)
    0 0 0 0
        Adolescents (12-17 years)
    0 0 0 0
        Adults (18-64 years)
    5 10 9 24
        From 65 to 84 years
    8 4 5 17
        85 years and over
    0 0 0 0
    Title for AgeContinuous
    Units: years
        median (full range (min-max))
    67 (46 to 74) 56 (36 to 80) 63 (48 to 75) -
    Title for Gender
    Units: subjects
        Female
    5 5 8 18
        Male
    8 9 6 23

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received 4 placebo subcutaneous (SC) injections (one injection every 4 weeks) for 16 weeks during double-blind treatment phase.

    Reporting group title
    Fulranumab 1 milligram (mg)
    Reporting group description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 1 mg for 16 weeks during double-blind treatment phase.

    Reporting group title
    Fulranumab 3 mg
    Reporting group description
    Subjects received 4 SC injections (one injection every 4 weeks) of fulranumab 3 mg for 16 weeks during double-blind treatment phase.
    Reporting group title
    Placebo
    Reporting group description
    Subjects who received placebo in treatment phase were followed for 24 weeks in this period.

    Reporting group title
    Fulranumab 1 mg
    Reporting group description
    Subjects who received fulranumab 1 mg in treatment phase were followed for 24 weeks in this period.

    Reporting group title
    Fulranumab 3 mg
    Reporting group description
    Subjects who received fulranumab 3 mg in treatment phase were followed for 24 weeks in this period.
    Reporting group title
    Placebo
    Reporting group description
    Subjects who received placebo in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.

    Reporting group title
    Fulranumab 1 mg
    Reporting group description
    Subjects who received fulranumab 1 mg in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.

    Reporting group title
    Fulranumab 3 mg
    Reporting group description
    Subjects who received fulranumab 3 mg in treatment phase were followed for up to 24 weeks after the last injection of study drug in this follow-up phase. Subjects who discontinued from the 24-week follow-up phase were asked to enter the LSFU phase.

    Primary: Change from Baseline to Double-blind Last Observation Carried Forward (DB-LOCF) in Patient Global Assessment (PGA) Score

    Close Top of page
    End point title
    Change from Baseline to Double-blind Last Observation Carried Forward (DB-LOCF) in Patient Global Assessment (PGA) Score [1]
    End point description
    The PGA is a single item that the patient completes to indicate their perception of their osteoarthritis status, on an 11-point numerical rating scale from 0 (Very Good) to 10 (Very Bad).The intent-to-treat (ITT) analysis set was defined as all randomized subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects who were evaluable for this outcome measure at specific timepoint.
    End point type
    Primary
    End point timeframe
    Baseline, Weeks 5, 9, 13, 17 and DB-LOCF
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistical analysis was performed for this outcome measure due to the small number of subjects subsequent to premature closure of the study.
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: units on scale
    arithmetic mean (standard deviation)
        Baseline (n=13,14,14)
    8.2 ± 1.28
    7.5 ± 1.22
    8.1 ± 1.27
        Change at Week 5 (n=13,13,13)
    -1.6 ± 2.02
    -2 ± 2.48
    -3.9 ± 3.15
        Change at Week 9 (n=8,9,8)
    -2.1 ± 2.17
    -3.2 ± 2.95
    -3.8 ± 3.37
        Change at Week 13 (n=8,6,6)
    -2.4 ± 2.07
    -4 ± 2.53
    -5.5 ± 3.62
        Change at Week 17 (n=7,5,6)
    -2.7 ± 2.43
    -3.4 ± 3.29
    -5.3 ± 2.94
        Change at DB-LOCF (n=13,13,13)
    -1.8 ± 2.12
    -2.4 ± 2.79
    -4.1 ± 2.9
    No statistical analyses for this end point

    Primary: Number of Subjects With Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability

    Close Top of page
    End point title
    Number of Subjects With Treatment-Emergent Adverse Events as a Measure of Safety and Tolerability [2]
    End point description
    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
    End point type
    Primary
    End point timeframe
    Baseline Up to 67 weeks
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistical analysis was performed for this outcome measure due to the small number of subjects subsequent to premature closure of the study.
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: subjects
    10
    9
    9
    No statistical analyses for this end point

    Secondary: Change from Baseline to Double-Blind Phase, Last Observation Carried Forward (DB-LOCF) in Western Ontario and McMaster University Arthritis Index (WOMAC) Pain Subscale Score

    Close Top of page
    End point title
    Change from Baseline to Double-Blind Phase, Last Observation Carried Forward (DB-LOCF) in Western Ontario and McMaster University Arthritis Index (WOMAC) Pain Subscale Score
    End point description
    The WOMAC 3.1 is a multi-dimensional, osteoarthritis (OA) specific self-administered questionnaire using 24 questions with a 48-hour recall that are grouped into 3 subscales (pain, stiffness, and physical function) associated with hip or knee OA. Pain, stiffness, and physical function are rated on a scale of 0-10, where 0=no pain to 10=extreme pain in the WOMAC pain subscale score. The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects who were evaluable for this outcome measure at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Weeks 5, 9, 13, 17 and DB-LOCF
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: units on scale
    arithmetic mean (standard deviation)
        Baseline (n=13,14,14)
    7.8 ± 0.735
    7.7 ± 1.298
    7.54 ± 0.949
        Change at Week 5 (n=13,13,13)
    -1.88 ± 2.829
    -2.69 ± 2.591
    -4.22 ± 3.076
        Change at Week 9 (n=8,9,8)
    -3.13 ± 3.219
    -3.49 ± 2.907
    -4.45 ± 3.281
        Change at Week 13 (n=8,6,6)
    -3.03 ± 2.562
    -4.13 ± 2.762
    -5.33 ± 2.974
        Change at Week 17 (n=7,5,6)
    -3.4 ± 2.889
    -3.84 ± 3.436
    -5.37 ± 2.981
        Change at DB-LOCF (n=13,13,13)
    -2.55 ± 2.86
    -3.05 ± 2.81
    -4.35 ± 2.78
    No statistical analyses for this end point

    Secondary: Change from Baseline to Double-Blind Phase, Last Observation Carried Forward (DB-LOCF) in Western Ontario and McMaster University Arthritis Index (WOMAC) Physical Function Subscale Score

    Close Top of page
    End point title
    Change from Baseline to Double-Blind Phase, Last Observation Carried Forward (DB-LOCF) in Western Ontario and McMaster University Arthritis Index (WOMAC) Physical Function Subscale Score
    End point description
    The WOMAC 3.1 is a multi-dimensional, osteoarthritis (OA) specific self-administered questionnaire using 24 questions with a 48-hour recall that are grouped into 3 subscales (pain, stiffness, and physical function) associated with hip or knee OA. Pain, stiffness, and physical function is rated on a scale of 0-10, where 0=no difficulty to 10=extreme difficulty in performing daily activities in the WOMAC physical function subscale score. The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects who were evaluable for this outcome measure at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Weeks 5, 9, 13, 17 and DB-LOCF
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: units on scale
    arithmetic mean (standard deviation)
        Baseline (n=13,14,14)
    7.7873 ± 0.78279
    7.4118 ± 1.39164
    7.4664 ± 1.07738
        Change at Week 5 (n=13,13,13)
    -1.6878 ± 2.62939
    -2.2624 ± 2.25451
    -4.086 ± 3.04679
        Change at Week 9 (n=8,9,8)
    -3.0074 ± 2.697
    -3.098 ± 2.7188
    -4.3676 ± 3.17145
        Change at Week 13 (n=8,6,6)
    -2.8162 ± 2.68229
    -3.6569 ± 2.25269
    -5.3627 ± 2.89933
        Change at Week 17 (n=6,5,6)
    -3.1429 ± 2.97255
    -2.9765 ± 3.2642
    -5.3235 ± 2.99544
        Change at DB-LOCF (n=13,13,13)
    -2.3122 ± 2.90372
    -2.6063 ± 2.51069
    -4.3077 ± 2.86441
    No statistical analyses for this end point

    Secondary: Change From Baseline Through Week 20 in Daily Numerical Rating Scale (NRS) Score

    Close Top of page
    End point title
    Change From Baseline Through Week 20 in Daily Numerical Rating Scale (NRS) Score
    End point description
    The numerical rating scale (NRS) uses an 11-point scale to assess OA pain ranging from 0 to 10 with high scores representing greater symptom severity (0=no pain and 10=pain as bad as you can imagine). The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects who were evaluable for this outcome measure at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Weeks 1-4, 5-8, 9-12, 13-16 and 17-20
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: units on scale
    arithmetic mean (standard deviation)
        Baseline (n=13,14,14)
    7.6487 ± 1.14509
    7.7583 ± 1.50712
    7.5786 ± 1.41371
        Change at Week 1-4 (n=13,14,14)
    -1.8685 ± 2.52985
    -2.4267 ± 2.21047
    -3.3235 ± 2.74091
        Change at Week 5-8 (n=9,11,12)
    -2.1963 ± 3.27845
    -2.9145 ± 2.45779
    -3.6599 ± 2.88441
        Change at Week 9-12 (n=8,9,8)
    -2.6673 ± 3.11693
    -4.3294 ± 2.42345
    -4.522 ± 3.04014
        Change at Week 13-16 (n=8,6,6)
    -2.4083 ± 3.06946
    -3.9833 ± 2.76883
    -5.2206 ± 3.27274
        Change at Week 17-20 (n=4,5,6)
    -3.1072 ± 2.73635
    -3.3514 ± 3.21071
    -5.0778 ± 3.23901
    No statistical analyses for this end point

    Secondary: Change From Baseline to DB-LOCF in WOMAC Stiffness Subscale Score

    Close Top of page
    End point title
    Change From Baseline to DB-LOCF in WOMAC Stiffness Subscale Score
    End point description
    The WOMAC 3.1 is a multi-dimensional, osteoarthritis (OA) specific self-administered questionnaire using 24 questions with a 48-hour recall that are grouped into 3 subscales (pain, stiffness, and physical function) associated with hip or knee OA. Pain, stiffness, and physical function is rated on a scale of 0-10, where 0=no stiffness to 10=extreme stiffness in the WOMAC stiffness subscale score. The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug. Here 'n' signifies number of subjects who were evaluable for this outcome measure at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Weeks 5, 9, 13, 17 and DB-LOCF
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: units on scale
    arithmetic mean (standard deviation)
        Baseline (n=13,14,14)
    8.19 ± 0.778
    7.54 ± 1.461
    7.61 ± 0.964
        Change at Week 5 (n=13,13,13)
    -1.15 ± 2.436
    -2.5 ± 1.99
    -3.65 ± 2.947
        Change at Week 9 (n=8,9,8)
    -2.13 ± 2.031
    -3.33 ± 2.264
    -4.44 ± 3.62
        Change at Week 13 (n=8,6,6)
    -2.75 ± 2.236
    -4.08 ± 1.8
    -5.75 ± 2.877
        Change at Week 17 (n=7,5,6)
    -2.86 ± 2.41
    -3.1 ± 2.133
    -5.42 ± 2.71
        Change at DB-LOCF (n=13,13,13)
    -2.19 ± 2.57
    -3.12 ± 2.247
    -3.92 ± 2.985
    No statistical analyses for this end point

    Secondary: Change from Baseline Through Double-blind Phase in Medical Outcomes Study (MOS) Sleep Subscale Scores

    Close Top of page
    End point title
    Change from Baseline Through Double-blind Phase in Medical Outcomes Study (MOS) Sleep Subscale Scores
    End point description
    The MOS Sleep Scale (acute version) contains 12 items that address aspects of sleep. Six subscale scores may be calculated including: daytime somnolence, sleep disturbances, snoring, shortness of breath or headache upon awaking, adequacy of sleep and amount of sleep plus a summary index of sleep disturbances. A higher score indicates worse sleep in most domains, but the amount of sleep and adequacy of sleep are scored in the opposite direction. The primary subscale of interest in this study is daytime somnolence. The ITT analysis set was defined as all randomized subjects who received atleast 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline through Double-blind Phase
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    0 [3]
    0 [4]
    0 [5]
    Units: units on scale
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Notes
    [3] - Analysis of this endpoint was not done because the program was terminated.
    [4] - Analysis of this endpoint was not done because the program was terminated.
    [5] - Analysis of this endpoint was not done because the program was terminated.
    No statistical analyses for this end point

    Secondary: Change From Baseline Through Double Blind Phase in Short-Form-36 Health Survey (SF-36) Subscale Score

    Close Top of page
    End point title
    Change From Baseline Through Double Blind Phase in Short-Form-36 Health Survey (SF-36) Subscale Score
    End point description
    The Short Form-36 (SF-36) is a self-administered, generic, 36-item questionnaire designed to evaluate 8 domains of functional health and well being: physical and social functioning, physical and emotional role (rolephysical, role-emotional) limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Baseline through Double-Blind Phase
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    0 [6]
    0 [7]
    0 [8]
    Units: units on scale
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Notes
    [6] - Analysis of this endpoint was not done because the program was terminated.
    [7] - Analysis of this endpoint was not done because the program was terminated.
    [8] - Analysis of this endpoint was not done because the program was terminated.
    No statistical analyses for this end point

    Secondary: Number of Subjects With Additional Analgesics Medication use Through Double-blind Phase

    Close Top of page
    End point title
    Number of Subjects With Additional Analgesics Medication use Through Double-blind Phase
    End point description
    Use of other OA pain medication was recorded weekly during the study. The ITT analysis set was defined as all randomized subjects who received at least 1 dose of study drug.
    End point type
    Secondary
    End point timeframe
    Up to 67 weeks
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    0 [9]
    0 [10]
    0 [11]
    Units: subjects
    Notes
    [9] - Analysis of this endpoint was not done because the program was terminated.
    [10] - Analysis of this endpoint was not done because the program was terminated.
    [11] - Analysis of this endpoint was not done because the program was terminated.
    No statistical analyses for this end point

    Secondary: Number of Subjects who Developed Antibodies to Fulranumab

    Close Top of page
    End point title
    Number of Subjects who Developed Antibodies to Fulranumab
    End point description
    Number of subjects who developed antibodies to fulranumab were assessed.
    End point type
    Secondary
    End point timeframe
    Up to 67 weeks
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    13
    14
    14
    Units: subjects
    0
    0
    0
    No statistical analyses for this end point

    Secondary: Plasma Concentrations for Fulranumab

    Close Top of page
    End point title
    Plasma Concentrations for Fulranumab
    End point description
    Plasma Concentrations for Fulranumab were assessed.
    End point type
    Secondary
    End point timeframe
    Up to 67 weeks
    End point values
    Placebo Fulranumab 1 milligram (mg) Fulranumab 3 mg
    Number of subjects analysed
    0 [12]
    0 [13]
    0 [14]
    Units: nanogram/milliliter (ng/mL)
        arithmetic mean (standard deviation)
    ±
    ±
    ±
    Notes
    [12] - Due to less number of subjects treated, only few samples were collected. No PK analyses was done.
    [13] - Due to less number of subjects treated, only few samples were collected. No PK analyses was done.
    [14] - Due to less number of subjects treated, only few samples were collected. No PK analyses was done.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Up to 67 weeks
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received 4 placebo subcutaneous (SC) injection (one injection every 4 week) for 16 weeks during double blind treatment phase (Period 1) and were followed-up for 24 weeks in follow-up phase (Period 2). Subjects who received placebo and discontinued from the double-blind phase and did not enter the post-treatment follow-up phase were followed-up for up to 24 weeks in LSFU phase (Period 3). Subjects who discontinued from the post-treatment follow-up phase were followed-up for 24 weeks in LSFU (Period 3).‌‌

    Reporting group title
    Fulranumab 3 mg
    Reporting group description
    Subjects received fulranumab 3 mg injection every 4 weeks for 16 weeks during double-blind treatment phase and were followed-up for 24 weeks in follow-up phase (Period 2). Subjects who received Fulranumab 3 mg and discontinued from the double-blind phase and did not enter the post-treatment follow-up phase were followed-up for up to 24 weeks in LSFU phase (Period 3). Subjects who discontinued from the post-treatment follow-up phase were also followed-up for 24 weeks in LSFU (Period 3).‌‌‌‌

    Reporting group title
    Fulranumab 1 mg
    Reporting group description
    Subjects received fulranumab 1 mg injection every 4 weeks for 16 weeks during double-blind treatment phase and were followed-up for 24 weeks in follow-up phase (Period 2). Subjects who received Fulranumab 1 mg and discontinued from the double-blind phase and did not enter the post-treatment follow-up phase were followed-up for up to 24 weeks in LSFU phase (Period 3). Subjects who discontinued from the post-treatment follow-up phase were followed-up for 24 weeks in LSFU (Period 3).‌‌‌

    Serious adverse events
    Placebo Fulranumab 3 mg Fulranumab 1 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 13 (0.00%)
    2 / 14 (14.29%)
    2 / 14 (14.29%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Ankle Fracture
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Haemoglobin Decreased
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Carotid Artery Stenosis
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular Accident
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Placebo Fulranumab 3 mg Fulranumab 1 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 13 (84.62%)
    11 / 14 (78.57%)
    11 / 14 (78.57%)
    Vascular disorders
    Flushing
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Hypertension
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Hypotension
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Labile Blood Pressure
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Orthostatic Hypotension
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    0
    0
    2
    Immune system disorders
    Drug Hypersensitivity
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    General disorders and administration site conditions
    Influenza Like Illness
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    0
    Peripheral Swelling
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Psychiatric disorders
    Adjustment Disorder with Depressed Mood
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Reproductive system and breast disorders
    Erectile Dysfunction
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Injury, poisoning and procedural complications
    Ankle Fracture
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Fall
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Foot Fracture
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Ligament Sprain
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Muscle Strain
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    1 / 14 (7.14%)
         occurrences all number
    0
    1
    1
    Stress Fracture
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Investigations
    Blood Potassium Decreased
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Blood Pressure Decreased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Blood Pressure Diastolic Decreased
         subjects affected / exposed
    4 / 13 (30.77%)
    2 / 14 (14.29%)
    3 / 14 (21.43%)
         occurrences all number
    7
    3
    3
    Blood Pressure Systolic Decreased
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 14 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    2
    0
    2
    Heart Rate Decreased
         subjects affected / exposed
    2 / 13 (15.38%)
    3 / 14 (21.43%)
    4 / 14 (28.57%)
         occurrences all number
    2
    6
    6
    Orthostatic Heart Rate Response Increased
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Weight Decreased
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Weight Increased
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Cardiac disorders
    Atrial Fibrillation
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Diaphragmalgia
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    0
    Blood and lymphatic system disorders
    Lymphadenopathy
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    1
    Paraesthesia
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Sciatica
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Sinus Headache
         subjects affected / exposed
    0 / 13 (0.00%)
    1 / 14 (7.14%)
    0 / 14 (0.00%)
         occurrences all number
    0
    1
    0
    Eye disorders
    Retinal Tear
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Gastrointestinal disorders
    Abdominal Pain
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Diarrhoea
         subjects affected / exposed
    0 / 13 (0.00%)
    2 / 14 (14.29%)
    0 / 14 (0.00%)
         occurrences all number
    0
    2
    0
    Skin and subcutaneous tissue disorders
    Skin Lesion
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    2 / 13 (15.38%)
    1 / 14 (7.14%)
    2 / 14 (14.29%)
         occurrences all number
    2
    1
    2
    Back Pain
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 14 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    2
    0
    2
    Musculoskeletal Pain
         subjects affected / exposed
    3 / 13 (23.08%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    3
    0
    0
    Neck Pain
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Osteoarthritis
         subjects affected / exposed
    2 / 13 (15.38%)
    0 / 14 (0.00%)
    2 / 14 (14.29%)
         occurrences all number
    3
    0
    3
    Rotator Cuff Syndrome
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    0 / 13 (0.00%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    Lower Respiratory Tract Infection
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    1
    Sinusitis
         subjects affected / exposed
    1 / 13 (7.69%)
    1 / 14 (7.14%)
    1 / 14 (7.14%)
         occurrences all number
    1
    1
    1
    Upper Respiratory Tract Infection
         subjects affected / exposed
    1 / 13 (7.69%)
    0 / 14 (0.00%)
    0 / 14 (0.00%)
         occurrences all number
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    31 Oct 2014
    Amendment INT-1 included the following changes: assessment for efficacy variables of Western Ontario and McMaster University Arthritis Index (WOMAC) and patient global assessment (PGA) were added based on health authority feedback for efficacy analysis after discontinuation of treatment; clarification to improve performance of assessments and conduct of study; and minor errors were noted.
    06 Feb 2015
    Amendment INT-2 included the: Clarification and consistency with guidelines.
    09 Feb 2015
    Amendment INT-3 included the following changes: Addition of criteria to be used to alert the Independent Data Monitoring Committee (IDMC) to review events of interest (neurologic) and reference to criteria to be used by the IDMC for decisions related to the further conduct of the study based on prespecified safety based criteria (for joint replacement, neurologic, sympathetic, hepatic and renal events of interest, ie, stopping criteria); clarification to improve performance of assessments and conduct of study and minor errors were noted.
    14 Jul 2015
    Amendment INT-4 included the following changes: Changes requested by ethics committees and health authorities to clarify study conduct and/or subject; Changes to clarify study conduct.
    14 Dec 2015
    Amendment INT-5 included the following changes: Respond to regulatory authority request to prohibit resumption of dosing for subjects who develop joint events of interests; respond to regulatory authority requests to include an assessment for carpal tunnel syndrome (CTS), at each clinic visit during the treatment periods, and at dedicated clinic visits during the safety follow-up period; clarification of what is acceptable as opioid failure in U.S. and Canada as per FDA request; clarification that a medication that is contraindicated will qualify as a failure due to intolerability; clarify the assessments and address repeated questions from sites; clarify that fasting serum and urine samples are preferred for biomarker analysis; and minor errors were noted.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Due to discontinuation of fulranumab program by sponsor for strategic reasons, the study was closed to enrollment before being fully enrolled. Hence, the study results are limited to descriptive summaries of all safety data and select efficacy data.
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA